Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(12 sites)
China
Beijing Cancer Hospital, Beijing, Beijing Municipality Peking University Third Hospital, Beijing, Beijing Municipality The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Fujian Hunan Cancer Hospital, Changsha, Hunan Nanjing Drum Tower Hospital, Nanjing, Jiangsu The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu The Affiliated Hospital of Qingdao University, Qingdao, Shandong The Affiliated Hospital of Qingdao University, Qingdao, Shandong Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital, Chengdu, Sichuan The Second Hospital of Tianjin Medical University, Tianjin, Tianjin Municipality Fudan University Cancer Hospital, Shanghai